New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
06:31 EDTIMGNImmunoGen announces preclinical findings for IMGN779
In preclinical findings reported at EHA, IMGN779 demonstrated potent, targeted activity against primary AML patient cells in vitro. IMGN779 can selectively kill leukemic cells (blasts) while sparing normal hematopoietic stem cells. IMGN779 was found to be highly active against human AML xenografts in vivo, demonstrating potent and targeted activity. IMGN779 was well tolerated without delayed toxicity in animal models. IMGN779 is on track to become the company’s next wholly owned clinical-stage compound. ImmunoGen is preparing to submit the IMGN779 IND in mid-2015.
News For IMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
08:39 EDTIMGNNovartis initiates Phase 1 PCA062, triggering milestone payment to ImmunoGen
In a regulatory filing, ImmunoGen disclosed Novartis (NVS) Institutes for BioMedical Research notified ImmunoGen (IMGN) that Novartis had initiated Phase I, first-in-human clinical testing of a product candidate, PCA062, utilizing antibody-drug conjugate technology. Pursuant to the license taken under our 2010 Multi-Target Agreement, this start of clinical testing triggers a $5M milestone payment to ImmunoGen.
May 14, 2015
07:40 EDTIMGNImmunoGen data 'impressive,' says Oppenheimer
Subscribe for More Information
May 13, 2015
17:41 EDTIMGNImmunoGen to present mirvetuximab data at 2015 ASCO meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use